- Total cumulative dose (TCD) of anthracycline/taxane-based chemotherapy shortens survival by about 50% relative to doses of ≥85% in women with early breast cancer.
- Early dose cuts largely accounted for the effect.
Why this matters
- This is the first study to determine survival effect of cutting doses with third-generation chemotherapy.
- A similar association was previously established with first- and second-generation adjuvant chemotherapy.
- Retrospective cohort of 1302 Canadian patients with early breast cancer (HR-positive/negative, HER2-negative).
- TCD for adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-D) was calculated for 6 cycles.
- Early (FEC±D) was compared with late (D only) dose reductions.
- Funding: None declared.
- Only 16% of the cohort had TCD
- In multivariate analysis, TCD
- Early cumulative dose reductions (FEC±D
- Late cumulative dose reductions (FEC±D=100% cycles 1-3; D
- Observational design.